An Ancient Drug for a Modern Era: Minocycline for the Treatment of Multi-Drug-Resistant Acinetobacter baumannii.

Introduction: Infections caused by are a major cause of health concerns in the hospital setting. Moreover, the presence of extreme drug resistance in has made the scenario more challenging due to limited treatment options thereby encouraging the researchers to explore the existing antimicrobial agents to combat the infections caused by them. This study focuses on the susceptibility of multi-drug-resistant  (MDR-AB) strains to minocycline and also to colistin.

Methodology: A cross-sectional study was conducted from June 2022 to June 2023. One hundred isolates of​​​​​​ ​​​obtained from various clinical samples were sent to Central Laboratory, Department of Microbiology, Sree Balaji Medical College and Hospital, Chrompet, Chennai, India. The antimicrobial susceptibility testing was performed according to the Clinical and Laboratory Standards Institute (CLSI) guidelines, 2022. For the standard antibiotics, the disc diffusion method was performed. For minocycline and colistin, the minimum inhibitory concentration (MIC) was determined using an epsilometer strip (E-strip) test.

Results: In this study, 100 isolates of  were obtained, and 83% of the isolates were multi-drug-resistant. Among the MDR-AB, 50 (60%) were susceptible to minocycline and 40 (48%) were susceptible to colistin. Out of the 40 colistin-susceptible  strains, 29 (73%) were susceptible to minocycline with a statistically significant -value of <0.05. Among the 43 colistin-resistant  strains, 21 (53%) were susceptible to minocycline with a statistically significant -value of <0.05.

Conclusions: When taking into account the expense of treating carbapenemase-producing Gram-negative bacteria, colistin and minocycline can be used as an alternative drug as they have fewer side effects and are more affordable. Minocycline can be used as an alternative to colistin because it is feasible to convert from an injectable to an oral formulation.